<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR520.html">Part 520
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 520.2455  Tiamulin.
                            </h3>
                            <p class="depth0"><em>(a)</em> Specifications. (1) Each gram of soluble powder contains 450 milligrams (mg) tiamulin hydrogen fumarate.</p><p class="depth0"><em>(2)</em> Each milliliter (mL) of solution contains 125 mg (12.5 percent) tiamulin hydrogen fumarate.</p><p class="depth0"><em>(3)</em> Each mL of solution contains 123 mg (12.3 percent) tiamulin hydrogen fumarate.</p><p class="depth0"><em>(b)</em> Sponsors. See sponsor numbers in Sec. 510.600(c) of this chapter for use as in paragraph (d) of this section.</p><p class="depth0"><em>(1)</em> No. 058198 for products described in paragraphs (a)(1) and (a)(2) of this section.</p><p class="depth0"><em>(2)</em> No. 066104 for the product described in paragraph (a)(1) of this section.</p><p class="depth0"><em>(3)</em> No. 054771 for the product described in paragraph (a)(3) of this section.</p><p class="depth0"><em>(c)</em> Related tolerances. See Sec. 556.732 of this chapter.</p><p class="depth0"><em>(d)</em> Conditions of use in swine--(1) Amounts and indications for use. Administer in drinking water for 5 consecutive days:</p><p class="depth0"><em>(i)</em> 3.5 mg per (/) lb of body weight daily for treatment of swine dysentery associated with Brachyspira hyodysenteriae susceptible to tiamulin.</p><p class="depth0"><em>(ii)</em> 10.5 mg/lb of body weight daily for treatment of swine pneumonia due to Actinobacillus pleuropneumoniae susceptible to tiamulin.</p><p class="depth0"><em>(2)</em> Limitations. Use as only source of drinking water. Prepare fresh medicated water daily. Withdraw medication 3 days before slaughter following treatment at 3.5 mg/lb and 7 days before slaughter following treatment at 10.5 mg/lb of body weight. Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse reactions may occur. The effects of tiamulin on swine reproductive performance, pregnancy, and lactation have not been determined.
[70 FR 75017, Dec. 19, 2005, as amended at 74 FR 7180, Feb. 13, 2009; 75 FR 54492, Sept. 8, 2010; 77 FR 56770, Sept. 14, 2012; 78 FR 17596, Mar. 22, 2013; 80 FR 13229, Mar. 13, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
